Updates From Angiogenesis-2022
These podcasts are an editorially independent initiative with support by Roche. To learn more about Roche Ophthalmology, visit www.futureofvision.global
Updates from Angiogenesis 2022: The Phase 3 Faricimab Study Results
Presented by:
Robyn Guymer, MBBS, PhD, FRANZCO, FAHMS
John A. Wells, III, MD
Robyn Guymer, MBBS, PhD, FRANZCO, FAHMS
Principal Global Medical Director, F. Hoffman La Roche Ltd.
Centre for Eye Research Australia,
University of Melbourne
Melbourne, Australia
Dr. Guymer has been involved with the Centre for Eye Research Australia since 2009, is the deputy head of ophthalmology at the University of Melbourne and is an adjunct professor at Monash University as well as an honorary clinical research fellow at the Bionic Institute of Australia. She is the 2021 Victorian Honour Roll of Women Inductee, the recipient of the Macula Society’s 2020 W. Richard Green Award and Lecture and has been an invited speaker to various conferences for more than 20 years.
John A. Wells, III, MD
Palmetto Retina Center
West Columbia, South Carolina
Dr. Wells is a founder of Palmetto Retina Center in South Carolina and has published numerous papers on diabetic eye disease. In addition, he has served on the executive committee for the Age-Related Eye Disease Study 2, was the protocol chair for the Protocol T studies, and was the vice-chair for the Diabetic Retinopathy Clinical Research Network.
Updates from Angiogenesis 2022: The Need for a New Staging System for Diabetic Retinal Disease
Presented by:
Jennifer Sun, MD, MPH
Jonathan Russell, MD, PhD
Jennifer Sun, MD, MPH
Associate Professor of Ophthalmology, Harvard University Medical School
Chief of the Center for Clinical Eye Research and Trials of the Beetham Eye Institute, Joslin Diabetes Center
Boston, MA
In addition to her academic appointments at Harvard University Medical School, Dr. Sun serves as the Chair for the Diabetic Retinopathy Clinical Research Retina Network (DRCR.net) and has chaired multiple nationwide, multicenter studies addressing new treatments and methods of evaluation for diabetic eye disease. The paper Dr. Sun discusses in this podcast can be downloaded from https://doi.org/10.1016/j.ophtha.2020.10.008
Jonathan Russell, MD, PhD
Department of Ophthalmology & Visual Science
University of Iowa Hospitals and Clinics
Iowa City, IA
Dr. Russell is a board-certified retina specialist and an assistant professor of vitreoretinal disease and surgery at the University of Iowa Hospitals and Clinics, having recently been chief resident of vitreoretinal surgery and director of ocular trauma at Bascom Palmer Eye Institute in Miami. He is one of only six Heed Fellows to be supported by the Society of Heed Fellows for his residency and has published several papers. The paper Dr. Russell discusses in this podcast can be downloaded from https://doi.org/10.1007/s11892-021-01401-8.
Updates from Angiogenesis 2022: The Port Delivery System
Presented by:
David A. Eichenbaum, MD
Peter Campochiaro, MD
David A. Eichenbaum, MD
Partner and Director of Research
Retina Vitreous Associates of Florida
St. Petersburg, FL
Dr. Eichenbaum is a board-certified ophthalmologist fellowship-trained in diseases and surgery of the vitreous and retina. He completed the Medical Honors Program earning both his undergraduate and medical degree at the University of South Florida in Tampa. He completed his Ophthalmology residency at the University of South Florida where he served as Chief Resident. Dr. Eichenbaum completed his two-year Surgical Retina fellowship at Tufts New England Eye Center and Ophthalmic Consultants of Boston.
Peter Campochiaro, MD
Director, Retinal Cell and Molecular Laboratory
Professor of Ophthalmology
Wilmer Eye Institute/Johns Hopkins School of Medicine
Baltimore, MD
Dr. Campochiaro is the Director of the Retinal Cell and Molecular Laboratory and the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute in Baltimore, MD. He received his medical degree from Johns Hopkins and joined Wilmer in 1991. He has published more than 200 papers, has been involved in multiple clinical trials, and has been an invited lecturer for more than 20 years.
